Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France

被引:34
作者
Bekri, H.
Cohen, R.
Varon, E.
Madhi, F.
Gire, R.
Guillot, F.
Delacourt, C.
机构
[1] Ctr Hosp Intercommunal, Serv Pediat, F-94000 Creteil, France
[2] Ctr Hosp Intercommunal, Serv Pediat, F-94190 Villeneuve St Georges, France
[3] Hosp Europeen Georges Pompidou, Microbiol Lab, Ctr Natl Reference Pneumocoques, Paris 75, France
来源
ARCHIVES DE PEDIATRIE | 2007年 / 14卷 / 03期
关键词
empyema; pleural; pleural effusion; pneumococcus; vaccination; child;
D O I
10.1016/j.arcped.2006.12.010
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
It has been suggested that the incidence of childhood empyema have increased during the last years in France without clear explanation. Streptococcus pneumoniae is responsible for the vast majority of bacteriological documented cases. Potential prevention of pleural empyemas by the heptavalent pneumococcal conjugate vaccine is dependent on adequation between specific pneumococcal serogroups present in vaccine and those responsible for empyemas. Material and methods. - We retrospectively collected cases of pleural empyemas registered at the National Reference Center for pneumococci (December 2002 to February 2004). Thirty children, aged 4.1 +/- 3.3 (SD) years, were included. Results. - Ten specific serogroups were identified: 1, 3, 5, 613, 717, 9V, 14, 18C, 19A, and 23F. Serogroups 19A and 1 were the 2 dominant serogroups and represented 50% of cases. All children infected with serotype 19A were younger than 5 years, whereas scrotype 1 was identified in 80% of empyemas in children older than 5 years. Among the 30 patients enrolled, 20 (69%) were infected with erotypes not included in the conjugate vaccine. Conclusion. - These results thus limit the potential impact of the heptavalent pneumococcal conjugate vaccine on the frequency of pleural empyemas in children. (c) 2007 Elsevier Masson SAS. Tous droits reserves.
引用
收藏
页码:239 / 243
页数:5
相关论文
共 15 条
[1]   BTS guidelines for the management of pleural infection in children [J].
Balfour-Lynn, IM ;
Abrahamson, E ;
Cohen, G ;
Hartley, J ;
King, S ;
Parikh, D ;
Spencer, D ;
Thomson, AH ;
Urquhart, D .
THORAX, 2005, 60 :1-21
[2]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[3]   An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: Risk factors and microbiological associations [J].
Byington, CL ;
Spencer, LY ;
Johnson, TA ;
Pavia, AT ;
Allen, D ;
Mason, EO ;
Kaplan, S ;
Carroll, KC ;
Daly, JA ;
Christenson, JC ;
Samore, MH .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (04) :434-440
[4]  
COHEN R, 2005, MED ENFANCE, V2, P299
[5]   Clinical features, aetiology and outcome of empyema in children in the north east of England [J].
Eastham, KM ;
Freeman, R ;
Kearns, AM ;
Eltringham, G ;
Clark, J ;
Leeming, J ;
Spencer, DA .
THORAX, 2004, 59 (06) :522-525
[6]  
GESLIN P, 1997, CTR NATL REFERENCE P
[7]   The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II [J].
Hausdorff, WP ;
Bryant, J ;
Kloek, C ;
Paradiso, PR ;
Siber, GR .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :122-140
[8]   Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model [J].
Jakobsen, H ;
Sigurdsson, VD ;
Sigurdardottir, S ;
Schulz, D ;
Jonsdottir, I .
INFECTION AND IMMUNITY, 2003, 71 (05) :2956-2959
[9]   Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine [J].
Kaplan, SL ;
Mason, EO ;
Wald, ER ;
Schutze, GE ;
Bradley, JS ;
Tan, TQ ;
Hoffman, JA ;
Givner, LB ;
Yogev, R ;
Barson, WJ .
PEDIATRICS, 2004, 113 (03) :443-449
[10]   Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae [J].
Kyaw, MH ;
Lynfield, R ;
Schaffner, W ;
Craig, AS ;
Hadler, J ;
Reingold, A ;
Thomas, AR ;
Harrison, LH ;
Bennett, NM ;
Farley, MM ;
Facklam, RR ;
Jorgensen, JH ;
Besser, J ;
Zell, ER ;
Schuchat, A ;
Whitney, CG .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) :1455-1463